Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China

References

• Faderl S, Kantarjian HM, Talpaz M, et al Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998;9:3995–4019.
   Google Scholar
• Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol 2006;43:126–133.
   PubMed Web of Science ®Google Scholar
• Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247):1079–1082.
   PubMed Web of Science ®Google Scholar
• Faderl S, Kantarjian HM, Thomas DA, et al Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000;36:263–273.
   PubMed Web of Science ®Google Scholar
• Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:21–36.
   PubMed Web of Science ®Google Scholar
• Dombret H, Gabert J, Boiron JM, et al Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 2002;100:2357–2366.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–566.
   PubMed Web of Science ®Google Scholar
• Fang G, Kim CN, Perkins CL, et al CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to anti leukemic drugs. Blood 2000;96:2246–2253.
   PubMed Web of Science ®Google Scholar
• Beran M, Cao X, Estrov Z, et al Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998;4:1661–1672.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes JE, O'Brien S, et al Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003;101:97–100.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, et al Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038–1042.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ, et al Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928–1937.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E, et al Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530–3539.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Cortes JE, et al Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002;8:2167–2176.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Druker BJ, Sawyers CL, et al A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965–1971.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Scheuring U, et al Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 2002;16:2358–2365.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, Cortes J, et al Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396–4407.
   PubMed Web of Science ®Google Scholar
• Lee KH, Lee JH, Choi SJ, et al Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005;19:1509–1516.
   PubMed Web of Science ®Google Scholar
• Yanada M, Takeuchi J, Sugiura I, et al High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006;24:460–466.
   PubMed Web of Science ®Google Scholar
• de Labarthe A, Rousselot P, Huguet-Rigal F, et al Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007;109:1408–1413.
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimino G, et al Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007;109:3676–3678.
   PubMed Web of Science ®Google Scholar
• Yanada M, Naoe T. Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. Leuk Lymphoma 2006;47:1747–1753.
   PubMed Web of Science ®Google Scholar
• Towatari M, Yanada M, Usui N, et al Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004;104:3507–3512.
   PubMed Web of Science ®Google Scholar
• Giuseppe Cimino, Fabrizio Pane, Loredana Elia, et al The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. Haematologica 2006;91:377–380.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Smith TL, et al Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547–561.
   PubMed Web of Science ®Google Scholar
• Gleissner B, Gokbuget N, Bartram CR, et al Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002;99:1536–1543.
   PubMed Web of Science ®Google Scholar
• Arico M, Valsecchi MG, Camitta B, et al Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998–1006.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Carston M, Kollman C, et al Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001;97:1572–1577.
   PubMed Web of Science ®Google Scholar
• Marks DI, Aversa F, Lazarus HM. Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options. Bone Marrow Transplant 2006;38:467–475.
   PubMed Web of Science ®Google Scholar
• Laughlin MJ, Eapen M, Rubinstein P, et al Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004;351:2265–2275.
   PubMed Web of Science ®Google Scholar
• Burke MJ, Trotz B, Luo X, et al Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant 2009;43:107–113.
   PubMed Web of Science ®Google Scholar
• Oehler VG, Gooley T, Snyder DS, et al The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007;109:1782–1789.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim YJ, Min CK, et al The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005;105:3449–3457.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Stadler M, et al Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005;106:458–463.
   PubMed Web of Science ®Google Scholar